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Abstract 13 
The majority of probiotic bacteria belong to the genus Lactobacillus which includes a large 14 
number of safe species integral to fermented food production. 15 
In the European Union the conversion of ensuing data into successful claims that are 16 
compliant with regulatory requirements has proved difficult. Furthermore, the study of 17 
lactobacilli has been challenging because of their phenotypic and genomic diversity.  18 
Here issues pertaining to the marketing authorization of novel foods and probiotics are 19 
outlined, taking Lactobacillus genus as reference. 20 
We highlight the drawbacks regarding the taxonomic characterization and the safety 21 
assessment of these bacteria and the validation of their beneficial mechanisms. 22 
 23 
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 25 
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 27 
Background 28 
In recent decades the Western diet has dramatically changed, being now characterized by 29 
high amounts of processed foods, refined sugars, refined fats and oils. This dietary shift has 30 
contributed to the increased incidence of chronic diseases such as type II diabetes, coronary 31 
heart disease and some cancers (Tilman and Clarke, 2014). To tackle the scale of this social 32 
problem, the European Union has been promoting actions that aim to meet the consumers’ 33 
need for safe, healthy, high quality and affordable food, and developing new dietary solutions 34 
and innovations focused on preventing chronic diseases and disorders 35 
(https://ec.europa.eu/programmes/horizon2020/en/h2020-section/societal-challenges). 36 
Although a number of novel functional foods have recently been introduced in the market, 37 
probiotics still remain the most popular. Probiotics are defined as live microorganisms that, 38 
when administered in adequate amounts, confer a health benefit on the host (Hill et al., 2014; 39 
FAO/WHO, 2001).  Many organisms now considered probiotic have traditionally been used 40 
as starter cultures in the manufacture of fermented foods. Probiotics available today comprise 41 
a much broader range of products including pharmaceuticals, a large variety of foods 42 
including juices, nutrition bars, infant formulas, relishes and condiments, sweeteners, waters, 43 
pizza crust, and other products such as gum, lozenges, dietary supplements, toothpaste, and 44 
cosmetics (Hoffman et al., 2014).  45 
The health and wellness claims associated with probiotics have led consumer demand for 46 
these products to grow at a fast pace: the market for probiotic ingredients is projected to reach 47 
USD 46.55 billion by 2020, with Europe and the Asian-Pacific region estimated to be the 48 
largest and the fastest-growing markets, respectively 49 
(http://www.marketsandmarkets.com/PressReleases/probiotics.asp).  50 
The lack of a well-established regulatory status of probiotic products at international level has 51 
led some manufacturers to market probiotic products in Europe without any pre-market 52 
approval (Caselli et al., 2013). This has led to the misuse of the term “probiotic”, which have 53 
been used for some foods in Europe even in the absence of an approved health claim 54 
(Sanders, 2015; Katan et al., 2012).  55 
Despite the fact that the European food industry has guidelines governing how to produce and 56 
market probiotic products, and the EU recognises probiotic bacteria as having the status of 57 
nutrients (EU regulation 1924/2006), substantial confusion reigns due to the application to 58 
probiotic foods of regulatory schemes initially designed to regulate pharmaceutical 59 
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development (reviewed in Hill et al., 2014). Different policies are used in the Member states 60 
which result in a lack of clear recommendations for the appropriate and accurate 61 
communication of probiotic statements to the different stakeholders including researchers, 62 
industries, legislators, consumers and health-care professionals, who are responsible for the 63 
different steps of bringing probiotic to the consumer (Van Buul and Brouns, 2015).  64 
At the same time as probiotics proliferate in the market, policy makers and regulators are 65 
simultaneously, and usually on an ad hoc basis, trying to critically develop the most 66 
appropriate regulatory structure for probiotics, which needs on the one hand to be rigorous in 67 
defining the level of accuracy required in claim dossiers, but on the other hand needs to be 68 
flexible enough to stimulate research and innovation, and thus encourage the release of new 69 
health-promoting products (Hoffman et al., 2014). The second part of this paradigm is 70 
arguably not working. 71 
The approval of health claims for probiotic-containing foods by the European Food Safety 72 
Authority (EFSA), which was appointed by the EU to provide scientific opinion on candidate 73 
claims and to protect the consumer from misleading information, has become very 74 
challenging due to the requirements for validating probiotic mechanisms in the target 75 
consumer, for proper strain characterization, and for conformity to required product 76 
characteristics (EFSA, 2016b; Miquel et al., 2015). Although a large volume of data about 77 
the beneficial effects of some probiotics has been obtained, precise mechanisms of probiotic 78 
action remain largely elusive except for a few examples, and thus the conversion into actual 79 
claims and compliance with the regulatory requirements in particular regions have proved 80 
difficult. 81 
Probiotic properties of Lactobacillus species include competitive exclusion of medically 82 
significant pathogens (Kanmani et al., 2013); immune system modulation (Klaenhammer et 83 
al., 2012), and the reduction of antibiotic therapy side effects (Lönnermark et al., 2010). 84 
From a regulatory point of view, the Lactobacillus genus includes 36 species that have been 85 
assigned Qualified Presumption of Safety (QPS) status by EFSA (EFSA, 2016a) and 12 86 
species are Generally Recognised as Safe (GRAS) by the U.S. Food and Drug Administration 87 
(FDA) (http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices). This means that 88 
they are suitable to be used as food/feed additives and they do not need a priori risk 89 
assessment.  90 
Furthermore, lactobacilli constitute 43% (84 species) of the total number of microorganisms 91 
with certified beneficial use (195 species representing 28 genera of phyla Actinobacteria, 92 
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Firmicutes and Proteobacteria), (Bourdichon et al., 2012), with 22 of them represented by 93 
strains that are patented in Europe due to their potential probiotic properties (Table 1). 94 
Despite their particular relevance, exploiting lactobacilli has always been very challenging 95 
due to their unusual phenotypic and genotypic diversity, unclear species identity and 96 
uncertain degree of relatedness between them and other commercially important lactic acid 97 
bacteria (Sun et al., 2015).  98 
In 2015, the genome sequences of almost all Lactobacillus type strains and some historically 99 
associated genera were determined (Sun et al., 2015; Zheng et al., 2015), thus providing a 100 
definitive genomic resource for mining all relevant phylogenetic and functional information. 101 
This data repository should also prove useful for understanding the species-restricted 102 
distribution of probiotic traits, thus supporting probiotic claim substantiation.  103 
Despite the unprecedented availability of genome sequences and increasing functional 104 
information about lactobacilli, the development of functional products containing these 105 
bacteria is challenged by the laborious nature of currently prescribed taxonomic 106 
characterization, the shortcomings regarding the validation of their beneficial mechanisms, 107 
and the drawbacks attached to determining their safety for consumption, issues that we will 108 
now expand upon. 109 
 110 
Taxonomic characterization of Lactobacillus probiotics 111 
Isolation and the full characterization of a candidate probiotic is the first essential 112 
requirement for a novel food marketing authorization and a health claim submission (EFSA, 113 
2017; EFSA 2016b). The taxonomic determination of the genus, the species and the strain 114 
contained in a probiotic product provides useful preliminary information regarding the main 115 
physiological and metabolic properties of the organism, and allows its discrimination from 116 
other closely related but potentially non-beneficial strains (ILSI 2013). 117 
The ideal characterization of microorganisms should include both genotypic and phenotypic 118 
tests; the combination of these data strands allows identity of the microorganism at both the 119 
species and strain level (EFSA, 2015). 120 
Taking account of the current state-of-the-art techniques for identification and molecular 121 
characterisation of microorganisms, EFSA recommends sequence analysis of at least two 122 
robust taxonomic markers (i.e. 16S rRNA gene sequence) or fully assembled and validated 123 
whole-genome sequence analysis for species identification. Genome sequencing is also 124 
suggested for strain typing, but this can also be achieved by other internationally accepted 125 
genetic typing molecular methods like whole genome mapping (WGM) or optical mapping 126 
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analysis. The bacterium is considered to be sufficiently characterised only when these two 127 
criteria are fulfilled. In addition, the EFSA advocates that the strain is deposited in at least 128 
one recognised international culture collection and encourages naming of strains according to 129 
the International Code of Nomenclature (EFSA, 2016b).   130 
The widespread use and characterization of lactobacilli are both hindered by the complex 131 
taxonomic structure of the genus, reflected in a poor correlation between the phylogenetic 132 
relationship and the physiological properties of Lactobacillus species (Zheng et al., 2015). 133 
Moreover, the ongoing description of novel species, whose number increased from 152 134 
(Salvetti et al., 2012) to more than 190 in the last 3 years 135 
(http://www.bacterio.net/lactobacillus.html), has resulted in significant taxonomy changes 136 
within the genus, causing confusion and leading to the mis-identification of lactobacilli.  137 
Although 16S rRNA gene sequence analysis is the standard method for Lactobacillus species 138 
identification thanks in part to the availability of up-to-date and internationally recognised 139 
databases (ie. EzTaxon, http://www.ezbiocloud.net/eztaxon), there are still shortcomings to 140 
this approach, such as the low taxonomic resolution afforded by 16S rRNA gene comparison 141 
especially when trying to separate closely related species (i.e Lb. plantarum/Lb. 142 
paraplantarum/Lb. pentosus or Lb casei/Lb. paracasei/Lb. rhamnosus). To overcome this, 143 
housekeeping genes as pheS, rpoA (Naser et al., 2007) and recA (Torriani et al., 2001) have 144 
been used as alternative phylogenetic markers which provide a higher discrimination between 145 
lactobacilli. Although the application of these molecular markers offers useful potential in the 146 
probiotic field, data interpretations by taxonomic experts remains crucial to ensure reliability 147 
of the identification results (Sanders et al., 2010).  148 
When the genomes of the type strains of around 175 Lactobacillus species were recently 149 
sequenced (Sun et al., 2015; Zheng et al., 2015), the ensuing analysis of the Average 150 
Nucleotide Identity (ANI) and the phylogenomics based on the core genes showed that the 151 
genus Lactobacillus is paraphyletic, intermixed with other five genera of order 152 
Lactobacillales (Pediococcus, Weissella, Leuconostoc, Oenococcus and Fructobacillus) and 153 
displaying a level of genomic diversity that is larger than that which is typical for a 154 
taxonomic family (Sun et al., 2015). Thus the (currently defined) genus Lactobacillus 155 
presents problems for strain and species distinction at short phylogenetic range, and problems 156 
for clade distinction at long phylogenetic range. None of this has aided providing industries, 157 
regulators or consumers with confident identification of commercial strains, as evidenced by 158 
some notable re-naming of high-profile strains such as La1 (Ashraf and Shah, 2014). 159 
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The vast genomic diversity of the genus Lactobacillus and its polyphyletic structure strongly 160 
suggests to us the necessity for the formal revaluation of its taxonomic scheme and its 161 
feasibility to be split in more homogeneous genera (Sun et al., 2015; Salvetti et al., 2012). 162 
The creation of more uniform taxonomic nuclei within the Lactobacillus genus is also 163 
expected to help prevent mis-identification issues which are still the major cause of 164 
mislabelling of probiotic food products reported worldwide (Hill et al., 2016; Van Loveren et 165 
al., 2012). This is not only essential to protect consumers from incorrect information, as food 166 
marketers sometimes give their probiotic strains trade names such as ‘Lactobacillus 167 
immunitas’ or ‘Lactobacillus defensis’ (Katan et al., 2012), but also for correct scientific 168 
communication and knowledge exchange between regulatory agencies and health-care 169 
providers. 170 
Considering the data summarized in Table 1, it is noteworthy that incorrect names are 171 
enshrined both in the QPS list of EFSA and in the GRAS notices of the FDA such as Lb. 172 
cellobiosus (which should be replaced by Lb. fermentum) or Lb. casei subsp. rhamnosus 173 
(which is now Lb. rhamnosus)Furthermore, incorrect and trade/proprietary names are also 174 
found in the page dedicated to “Lactobacillus” in the MedlinePlus website, the National 175 
Institutes of Health’s website for patients and health-care providers: 176 
 (https://www.nlm.nih.gov/medlineplus/druginfo/natural/790.html).  177 
Probiotic stakeholders are encouraged to refer to international organisations such as the 178 
Subcommittee on the Taxonomy of Bifidobacterium, Lactobacillus and related organisms 179 
(http://icsp.org/subcommittee/bifidobacterium_lactobacillus/) which provides the probiotic 180 
community with updated classification tools for research and application of Lactobacillus 181 
probiotics (Mattarelli et al., 2014), as well as the International Life Science Institute, the 182 
International Scientific Association for Probiotics and Prebiotics, the International Dairy 183 
Federation, the European Food and Feed Culture Association, whose panels of experts can 184 
advise which technique is necessary and sufficient so that probiotic strains are correctly 185 
labelled and ensure clear communication between stakeholders involved.  186 
Validation of the probiotic potential of Lactobacillus spp. 187 
Approval of probiotic claims requires a full analysis of the mechanism(s) of action which is 188 
usually accomplished through a combination of in vitro and in vivo screening assays and 189 
“omics” technologies (Papadimitriou et al., 2015).) 190 
Powerful genetic and omics analyses have allowed the investigation of the molecular 191 
mechanisms that underpin probiotic properties and unveiled a plethora of genes as potential 192 
markers for the identification of probiotic strains, including genes/proteins involved in stress 193 
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response (acid and bile), adhesion, metabolism of human milk oligosaccharides and mucus, 194 
modulation of the immune system, production of antimicrobial compounds, quorum sensing, 195 
production of nutrients and other beneficial processes such as the metabolism of prebiotics 196 
(Ventura et al,. 2009; Lebeer et al., 2008). 197 
Validation of genome-based analysis with experimental approaches is necessary to link 198 
annotated gene sequences to their predicted traits, and this also represents a prerequisite for 199 
the construction of databases of probiotic markers with translational predictive value. 200 
Although the molecular analyses of probiotic properties do not entirely substitute for 201 
experimental tests, in silico approaches constitute an important step in the development of 202 
more efficient and precise screens for probiotic strains. 203 
EFSA approves health claims if the substantiation is based on generally accepted scientific 204 
evidence, using an assessment process of the highest possible standard (EC No. 1924/2006). 205 
The approach adopted shall consist primarily of human studies and according to a hierarchy 206 
of study designs which supports the relative strength of evidence (EC. No. 353/2008).  207 
Although a workflow of the key steps in the process of authorisation of health claims made 208 
on foods is outlined by EFSA (EFSA, 2017; EFSA, 2016b), no official procedures or 209 
workflows for selecting probiotics are available (i.e. validated biomarkers for in vitro 210 
screening) and this makes it difficult to determine the real probiotic potential of 211 
microorganisms and the physiological effect they exert.  212 
The lack of sufficient efficacy data has undermined the acceptance of health claim dossiers: 213 
in the foodprobiotic area, none of over 300 nutrition and health claims submitted to EFSA 214 
since 2009 was considered sufficiently substantiated 215 
(http://ec.europa.eu/nuhclaims/)(Glanville et al., 2015).  216 
In addition, successful probiotic claim substantiation is also impeded by EU laws which do 217 
not recognise the possibility that food can prevent, treat or cure a disease, leaving scientists, 218 
marketers, food producers and also legislators in an ambiguous impasse (Katan et al., 2012).  219 
In a recent attempt to solve these issues, EFSA released updated general scientific guidance 220 
for stakeholders on health claim applications in which the Panel on Dietetic Products, 221 
Nutrition and Allergies (NDA) outlines the principles to be applied for the scientific 222 
evaluation of health claim applications and the issues to be considered by applicants for the 223 
compilation of applications (EFSA, 2017; EFSA, 2016b).  224 
Furthermore, the EFSA also updated the guidance document on the scientific requirements 225 
for the substantiation of health claims related to gut and immune function (EFSA, 2016c; 226 
EFSA, 2015) where it provides clearer definitions of the supporting evidence required for 227 
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health claims applied to food products, the reproducibility and consistency of the effect of the 228 
constituent for which a health claim is proposed, the definition of physiological effect in the 229 
context of food and the use of authorised health claims by stakeholders. Focusing on the 230 
characterisation of the claimed effect of the constituent (including probiotic microorganisms); 231 
the EFSA opinion specifically highlights the fact that data on genetic regions derived through 232 
whole genome sequencing, in combination with other experiments performed in vivo, is a 233 
solid approach to characterise the mechanisms at the basis of a specific function or health 234 
benefit (EFSA, 2015). 235 
Lactobacilli occupy a particular position in this context: of the submitted nutritional and 236 
health claim applications mentioned above, 264 submissions (all of them rejected by EFSA) 237 
include strains belonging to 15 Lactobacillus species, either developed as sole active 238 
ingredients or in combination with other microorganisms, which in turn refer to the 239 
functioning of nine specific organs and systems, in particular the gut (61% of the claims with 240 
Lactobacillus strains) (Figure 1). 241 
The most numerous species among these applications are Lb. plantarum (28%), Lb. 242 
paracasei (11%), Lb. rhamnosus (10%) and Lb. casei (10%): a review of the literature in 243 
PubMed showed that strains belonging to these species for which a claim has been submitted 244 
are cited in more than 700 papers, with L. rhamnosus GG and L. casei Shirota covering more 245 
than 200 papers each.  246 
Although the genus Lactobacillus is one of the most investigated genera in food 247 
microbiology and human nutrition, surprisingly only 7-8% of the Lactobacillus species (15 248 
species out of more than 190) have been formally explored as probiotics by way of a health 249 
claim submitted to the regulatory agencies. 250 
A detailed analysis of the nutrition and health claims that feature Lactobacillus strains 251 
revealed that the main reasons of rejection were i) insufficient characterization of the food 252 
and poor scientific assessment of the claimed effect (i.e. Lb. plantarum 299; EFSA, 2010), ii) 253 
the absence of a beneficial physiological effect based on the scientific evidence assessed (Lb. 254 
acidophilus NCFM ATCC SD5221; EFSA, 2011) iii) the non-recognition of the property of 255 
preventing, treating or curing a human disease to food (i.e. Lb. paracasei LPC 01; EFSA, 256 
2012a).   257 
Since the majority of the nutrition and health claims that involve lactobacilli target the 258 
functioning of the gastrointestinal tract and the improvement of gut health, the application of 259 
the novel directives provided in the recent guidances by EFSA is expected to support the 260 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
successful resubmission of these claims and may allow the marketing authorization of new 261 
Lactobacillus products.  262 
In this framework, the genome of Lactobacillus type strains (Sun et al., 2015) and probiotic 263 
strains (e.g. Lb. rhamnosus GG, Kankainen et al., 2009) constitute a solid basis for claim 264 
substantiation in combination with in vivo approaches (as suggested by EFSA), but they also 265 
expand the pool of Lactobacillus species to be investigated as probiotics (i.e. other 266 
Lactobacillus species isolated from humans such as Lb. gastricus, Lb. antri or Lb. kalixensis 267 
(Roos et al., 2005) and contribute to the creation of a custom database of Lactobacillus 268 
probiosis marker genes. 269 
Finally, defining the mechanisms of probiotic action through genome-based analysis may 270 
also be useful for the optimization of some critical parameters during the industrial process: 271 
the production of bioactive metabolites, in fact, can be predicted from the genome sequence, 272 
facilitating construction of metabolic models that incorporate the biochemical reactions of an 273 
organism together with information on biomass assembly reaction and exchange fluxes with 274 
the external enviroment (Fondi et al., 2015).  275 
The development of such a strategy allows predictive modelling of optimal industrial 276 
conditions to be used, facilitating the selection and optimization of probiotics and/or 277 
beneficial compounds production (Saulnier et al., 2011). 278 
 279 
Safety assessment of Lactobacillus species 280 
The safety of probiotics is linked to their intended use, the potential vulnerability of the 281 
consumer or patient, the dose and duration of consumption and both the manner and 282 
frequency of administration. 283 
In the EU, a priori safety is generally accepted for microorganisms that have been awarded 284 
QPS status. Microorganisms that have not been used in food in Europe prior to 1997 must to 285 
be assessed for their safe use before being authorized for sale on the European market, as 286 
stated by the UE 97/618/EC recommendation and regulation N. 258/97. 287 
In 2010, Sanders and colleagues described the factors that should be addressed to assess the 288 
safety of probiotics, in particular i) the immunological effects in certain vulnerable 289 
populations including the immunocompromised, the critically ill, patients with inflammatory 290 
bowel disease and full-term or premature infants with undeveloped immune functions; and ii) 291 
the microbiological and metabolic issues, including the correct identification and labelling of 292 
probiotic bacteria, the evidence for their long-term colonization of the host, the assessment of 293 
antibiotic resistance and its transferability, their genetic stability and viability, their 294 
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pathogenicity/toxicogenicity, and their ability to produce biogenic amines (Sanders et al., 295 
2010). 296 
More recently, Miquel and colleagues (2015) reported an updated list of criteria considered as 297 
essential for the safety of probiotic products (required for both novel food and health claim 298 
regulation) including the survival in GI tract conditions, preservation of the homeostasis of 299 
the gut barrier components, adhesion and translocation risk, and metabolic and other remote 300 
effects (such as genotoxicity and platelet aggregation) (Miquel et al., 2015). 301 
It is evident that the lack of the mechanistic understanding of probiotic activity together with 302 
incorrect species identification and mislabelling of probiotics (discussed above) is a major 303 
drawback for the prediction of safety of a probiotic intervention and for the creation of an 304 
exhaustive list of criteria to be assessed (Sanders et al., 2010). 305 
Due to these shortcomings, the biological relevance of the requirements listed above is still 306 
the subject of debate and no formal guidance exists for the safety assessment of probiotic 307 
bacteria (Miquel et al., 2015).  308 
As already mentioned, the majority of Lactobacillus species have a long history of apparently 309 
safe use in industrial and agricultural applications; moreover, they are among the dominant 310 
populations in microbial communities of traditional fermented foods and are part of natural 311 
starter cultures. Despite being occasionally involved in human diseases (like bacteremia 312 
and/or systemic septicaemia in already immunocompromised patients), the daily consumption 313 
of large quantities of lactobacilli in a variety of fermented foods by people of all ages and 314 
health statuses apparently does not have ill effects, and they have generally been considered 315 
to be non-pathogenic (EFSA, 2007).  316 
However, several intrinsic properties of lactobacilli related to their metabolic activities may 317 
be implicated in human health risk, such as the production of biogenic amines (histamine, 318 
tyramine, and others), bile salt deconjugase activity, enzymatic activities which may have 319 
undesirable toxicological effects (like azoreductases and nitroreductases), the degradation of 320 
hyaluronic acid, the platelet aggregation activity (Collins et al., 2012), or the colonization and 321 
the production of toxic metabolites (Bernardeau et al., 2008). In addition, a considerable 322 
number of antibiotic resistant lactobacilli has been reported, which could theoretically act as 323 
donors or reservoirs for antibiotic resistance genes, thus with the potential risk of transferring 324 
the genes to pathogenic bacteria in the food matrices as well as in the gastrointestinal tract. 325 
The lack of official guidance for the safety assessment for Lactobacillus species with 326 
intended use as food or feed additives has led to the release of papers that address this issue 327 
inconsistently: in fact a search in PubMed shows publications that report different 328 
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combinations of assays (from genome-based techniques and phenotypic assays, to the use of 329 
mouse models and human clinical trials) providing only partial safety estimations which are 330 
also difficult to compare.  331 
Because apparently no particular safety concerns exist for lactobacilli for use in the general 332 
population in foods at typical consumption levels, EFSA recommends that Lactobacillus 333 
strains be assessed for their susceptibility to antibiotics: in the guidance released in 2012, 334 
EFSA reports the Minimum Inhibitory Concentrations (MIC) cut-off values for nine 335 
antibiotics (ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, 336 
clindamycin, tetracycline and chloramphenicol) to define if the lactobacilli being used are 337 
susceptible or resistant to antimicrobials and thus their suitability for use as feed/food 338 
additives. In addition, EFSA proposes a scheme for antimicrobial resistance assessment 339 
including the analysis of the distribution of known antimicrobial resistance genes, based upon 340 
the Antibiotic Resistance database (ARDB, http://ardb.cbcb.umd.edu/) (EFSA, 2012b).   341 
Despite the presence of this specific guidance, some drawbacks still exist: the cut-off values 342 
are reported for only some groups of lactobacilli and not at species-by-species level 343 
(Goldstein et al., 2015), while the ARDB is an obsolete tool as it was most recently updated 344 
in 2009.  345 
Thanks to the recent explosion in the genome sequencing of microorganisms, other databases 346 
have been developed like the Comprehensive Antibiotic Resistance database (CARD, 347 
arpcard.mcmaster.ca/) and the Virulence Factor database (VFDB, 348 
http://www.mgc.ac.cn/VFs/), which, on one hand, allow the fast detection of putative 349 
antibiotic resistance genes or virulence factors, but, on the other hand, a big effort is required 350 
to assess if the “hits” or determinants identified in a given genome sequence represent a real 351 
safety concern. In fact, the trait of adhesion to the host is a virulence factor in pathogenic 352 
bacteria, but it may represent a marker of probiosis in health-promoting microorganisms. 353 
Furthermore, many traits considered as virulence determinants in the VFDB are mis-354 
annotated (e.g. proteins with membrane-spanning alpha helices may be mis-identified as 355 
toxins, and ATP-binding cassette proteins may be flagged simply because this class of 356 
proteins is associated with some virulence loci in pathogens). 357 
To tackle this particular issue in future, the availability of the genome sequences of all 358 
Lactobacillus type strains will be an invaluable resource for the forensic detection of bona 359 
fide antibiotic resistance determinants, virulence factors or other genes responsible for 360 
undesirable metabolite production in lactobacilli. The parallel execution of phenotypic assays 361 
on all lactobacilli such the determination of the antibiotic MIC will allow robust genotype-362 
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phenotype matching for the first time across the whole genus. Similarly, assays for traits such 363 
as the decarboxylase activity linked with biogenic amines production compared to genomic 364 
searches for the relevant determinants can provide a more robust body of knowledge upon 365 
which more specific databases for the analysis of the safety of lactobacilli can be developed. 366 
In addition to supporting researchers and scientists in achieving much more consistent data 367 
on Lactobacillus safety, these tools can also help regulatory agencies to define more precise 368 
recommendations (for instance, revised MIC cut-off values for all Lactobacillus species, if 369 
appropriate), which would be useful for the safe marketing authorization of new products 370 
containing lactobacilli.  371 
 372 
Conclusions 373 
In this perspective we highlight drawbacks in the scientific approach and the regulatory 374 
procedure to obtain market authorization for probiotics, taking the genus Lactobacillus as a 375 
reference. We believe that the unprecedented availability of the genomic, phenotypic and 376 
functional data of Lactobacillus strains (including type strains, non-probiotic strains, 377 
probiotic strains, and widely used starter cultures) represents the ideal resource for the 378 
development of new and more focused scientific protocols and regulatory procedure to assess 379 
the safety and the beneficial effects of Lactobacillus probiotics and for successful health 380 
claim substantiation. This compliance could then be further used as a rationale for probiotic 381 
microorganisms belonging to other genera as Bifidobacterium or Bacillus. 382 
Such a straightforward regulatory system would stimulate more systematic research and 383 
innovation in probiotics, ensure effective communication of probiotic knowledge to 384 
consumers and health-care providers, and strengthen their confidence in probiotic and health 385 
claims through coherent recommendations and product labels, and finally improve the 386 
industry with high-quality and profitable products (Sanders et al., 2015).  387 
A well-established framework for regulation and authorization of existing probiotics whereby 388 
the stakeholders agree almost unanimously is also necessary to face the next challenge for the 389 
market authorization of the next-generation probiotics belonging to ‘unconventional’ species 390 
isolated from the human gut, such as Faecalibacterium prausnitzii, Akkermansia muciniphila, 391 
and Eubacterium hallii, identified through our growing understanding of the composition of 392 
the gut microbiota and its role in health and disease.  393 
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Table 1. Lactobacillus species on the QPS list (EFSA), on the GRAS list (FDA), in the EFFCA inventory and 601 
for which a patent has been deposited (ESPACENET database). 602 
QPS list (EFSA)1 GRAS notice (FDA)2 EFFCA Inventory3 Patents (ESPACENET)4 
Lb. acidophilus 
Lb. amylolyticus 
Lb. amylovorus 
Lb. alimentarius 
‘Lb. aviaries’ 
Lb. brevis 
Lb. buchneri 
Lb. casei 
‘Lb. cellobiosus’ 
Lb. coryniformis 
Lb. crispatus 
Lb. curvatus 
Lb. delbrueckii 
Lb. diolivorans 
Lb. farciminis 
Lb. fermentum 
Lb. gallinarum 
Lb. gasseri 
Lb. helveticus 
Lb. hilgardii 
Lb. johnsonii 
Lb. kefiranofaciens 
Lb. kefiri 
Lb. mucosae 
Lb. panis 
Lb. collinoides 
Lb. paracasei 
Lb. paraplantarum 
Lb. pentosus 
Lb. plantarum 
Lb. pontis 
Lb. reuteri 
Lb. rhamnosus 
Lb. sakei 
Lb. salivarius 
Lb. sanfranciscensis 
Lb. acidophilus 
Lb. bulgaricus 
Lb. casei 
‘Lb. casei subsp. 
rhamnosus’ 
Lb. fermentum 
Lb. subsp. lactis 
Lb. lactis 
Lb. paracasei subsp. 
paracasei 
Lb. plantarum 
Lb. reuteri 
Lb. rhamnosus 
Lb. sakei 
 
Lb. acetotolerans 
Lb. acidifarinae 
Lb. acidipiscis 
Lb. acidophilus 
Lb. alimentarius 
Lb. amylolyticus 
Lb. amylovorus 
Lb. brevis 
Lb. buchneri 
Lb. cacaonum 
‘Lb. casei subsp. casei’ 
Lb. collinoides 
Lb. composti 
Lb. coryniformis subsp. 
coryniformis 
Lb. crispatus 
Lb. crustorum 
Lb. curvatus subsp. curvatus 
Lb. delbrueckii subsp. bulgaricus 
Lb. delbrueckii subsp. delbrueckii 
Lb. delbrueckii subsp. lactis 
Lb. dextrinicus 
Lb. diolivorans 
Lb. fabifermentans 
Lb. farciminis 
Lb. fermentum 
Lb. fructivorans 
Lb. frumenti 
Lb. gasseri 
Lb. ghanensis 
Lb. hammesii 
Lb. harbinensis 
Lb. helveticus 
Lb. hilgardii 
Lb. homohiochii 
Lb. hordei 
Lb. jensenii 
Lb. johnsonii 
Lb. kefiri 
Lb. kefiranofaciens subsp. 
kefiranofaciens 
Lb. kefiranofaciens subsp. 
kefirgranum 
Lb. kimchii 
Lb. kisonensis 
Lb. mali 
Lb. manihotivorans 
Lb. mindensis 
Lb. mucosae 
Lb. nagelii 
Lb. namurensis 
Lb. nantensis 
Lb. nodensis 
Lb. oeni 
Lb. otakiensis 
Lb. panis 
Lb. acidophilus 
Lb. brevis 
Lb. buchneri 
Lb. casei 
Lb. crispatus 
Lb. coryniformis 
Lb. delbrueckii 
Lb. fermentum 
Lb. gasseri 
Lb. helveticus 
Lb. iners 
Lb. johnsonii 
Lb. kefiranofaciens 
Lb. kitasatonis 
Lb. mucosae 
Lb. pentosus 
Lb. paracasei 
Lb. plantarum 
Lb. rhamnosus  
Lb. reuteri 
Lb. sakei 
Lb. salivarius 
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Lb. parabrevis 
Lb. parabuchneri 
Lb. paracasei subsp. paracasei 
Lb. parakefiri 
Lb. paralimentarius 
Lb. paraplantarum 
Lb. pentosus 
Lb. perolens 
Lb. plantarum subsp. plantarum 
Lb. pobuzihi 
Lb. pontis 
Lb. rapi 
Lb. reuteri 
Lb. rhamnosus 
Lb. rossiae 
Lb. sakei subsp. carnosus 
Lb. sakei subsp. sakei 
Lb. salivarius subsp.salivarius 
Lb. sanfranciscensis 
Lb. satsumensis 
Lb. secaliphilus 
Lb. senmaizukei 
Lb. siliginis 
Lb. similis 
Lb. spicheri 
Lb. suebicus 
Lb. sunkii 
Lb. tucceti 
Lb. vaccinostercus 
Lb. versmoldensis 
Lb. yamanashiensis 
1:EFSA Journal 2016; 14(7): 4522; 603 
2
. updated 20/11/2015;  604 
http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&sort=GRN_No&order=DESC&startrow=1&ty605 
pe=basic&search=Lactobacillus  606 
3: EFFCA Inventory of microorganisms with beneficial use (International Journal of Food Microbiology 2012, 607 
154, pp.87-97), http://www.effca.org/content/inventory-microorganisms  608 
4: updated 20/11/2015, search performed in Espacenet (http://worldwide.espacenet.com/) using the keywords 609 
“Lactobacillus” and “probiotic” in “Title” and “Title/Abstract”, respectively.  610 
 611 
  612 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
Figure caption 613 
Figure 1. Lactobacillus species involved in health claims applications (A) and the target organs/systems for 614 
which Lactobacillus species have a beneficial effect (B).  615 
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Highlights 
• The approval of health claims for probiotics has become very challenging  
• The amount of data for the genus Lactobacillus is a resource for regulatory 
procedures.   
• This Lactobacillus-centric compliance model can be a paradigm for other probiotic 
bacteria.  
